NQO1 expression in pancreatic cancer and its potential use as a biomarker

Applied Immunohistochemistry and Molecular Morphology

Volumn 16, Issue 1, 2008, Pages 24-31

  Awadallah, Nida S ^a   Dehn, Donna ^a   Shah, Raj J ^a   Russell Nash, S ^a   Chen, Yang K ^a   Ross, David ^a   Bentz, Joel S ^b   Shroyer, Kenneth R ^a,c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

EUS FNA; Immunohistochemistry; NQO1; Pancreatic adenocarcinoma; Tumor markers

Indexed keywords

AVIDIN; BIOLOGICAL MARKER; BIOTIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ADULT; ARTICLE; ASPIRATION BIOPSY; CANCER SURGERY; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOSCOPIC ECHOGRAPHY; FALSE POSITIVE RESULT; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; PANCREAS BIOPSY; PANCREAS CANCER; PANCREAS CELL; PANCREAS DUCT; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING;

BIOLOGICAL MARKERS; BIOPSY, FINE-NEEDLE; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); PANCREAS; PANCREATIC NEOPLASMS;

EID: 37549056508     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31802e91d0     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. American Cancer Society. Cancer Facts and Figures 2006. Atlanta, GA: American Cancer Society; 2006.
3. Li D, Keping X, Wolff R, et al. Pancreatic cancer. Lancet. 2004;363:1049-1057.
4. Hawes RH, Xiong Q, Waxman I, et al. A multispecialty approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol. 2000;95:17-31.
5. Bramhall SR, Allum WH, Jones AG, et al. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the epidemiological study. Br J Surg. 1995;82:111-115.
6. Faigel DO, Ginsberg GG, Bentz JS, et al. Endoscopic ultrasound-guided real-time fine-needle aspiration biopsy of the pancreas in cancer patients with pancreatic lesions. J Clin Oncol. 1997;15:1439-1443.
7. Nakamura T, Furukawa Y, Nakagawa H, et al. Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene. 2004;23:2385-2400.
8. Friess H, Ding J, Kleeff J, et al. Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. Cell Mol Life Sci. 2003;60:1180-1199.
9. Grutzmann R, Foerder M, Allginger I, et al. Gene expression profiles of microdissected pancreatic ductal adenocarcinoma. Virchows Arch. 2003;443:508-517.
10. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res. 2003;63:8614-8622.
11. Logsdon CD, Simeone DM, Binkley C, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 2003;63:2649-2657.
12. Yoshida K, Ueno S, Iwao T, et al. Screening of genes specifically activated in the pancreatic juice ductal cells from the patients with pancreatic ductal carcinoma. Cancer Sci. 2003;94:263-270.
13. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL, et al. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol. 2002;160:1239-1249.
14. Siegel D, Ross D. Immunodetection of NAD(P)H:quinone oxidorectase 1 (NQO1) in human tissues. Free Radic Biol Med. 2000;29:246-253.
15. Hammons GJ, Warren GJ, Blann WE, et al. Increased DTdiaphorase activity in transformed and tumorigenic pancreatic acinar cells. Cancer Let. 1995;96:9-14.
16. Lewis AM, Ough M, Hinkhouse MM, et al. Targeting NAD(P)H:-quinone oxidoreductase (NQO1) in pancreatic cancer. Mol Carcinog. 2005;43:215-224.
17. Lyn-Cook BD, Yan-Sanders Y, Moore S, et al. Increased levels of NAD(P)H:quinine oxidoreductase 1 (NQO1) in pancreatic tissues from smokers and pancreatic adenocarcinomas: a potential biomarker of early damage in the pancreas. Cell Biol Toxicol. 2006;22:73-80.
18. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol. 2001;25:579-586.
19. Apple SK, Hecht JR, Lewin DN, et al. Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis. Hum Pathol. 1999;30:123-129.
20. Boschman CR, Stryker S, Reddy JK, et al. Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas. Am J Pathol. 1994;145:1291-1295.
21. DiGiuseppe JA, Hruban RH, Goodman SN, et al. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol. 1994;101:684-688.
22. Suzuki T, Takano Y. Comparative immunohistochemical studies of p53 and proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions in pancreatic duct cell carcinomas. Jpn J Cancer Res. 1993;84:1072-1077.
23. Virkajarvi N, Paakko P, Soini Y. Association between p53 overexpression, cell proliferation, tumor necrosis and extent of apoptosis in operated pancreatic adenocarcinoma. APMIS. 1997; 105:765-772.
24. Day JD, DiGiuseppe JA, Yeo C, et al. Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol. 1996;27:119-124.
25. Safran H, Steinhoff M, Mangray S, et al. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol. 2001;24:496-499.
26. Koka V, Potti A, Koch M, et al. Role of immunohistochemical identification of HER-2/neu and detection of variability in overexpression in pancreatic carcinoma. Anticancer Res. 2002;22:1593-1598.
27. Potti A, Ganti AK, Tendulkar K, et al. HER-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma. Anticancer Res. 2003;23:2671-2674.
28. Tamiolakis D, Venizelos I, Simopoulos C, et al. Correlation of immunohistochemically detected HER-2/neu (c-erbB-2) with histological stage and perineural invasion in pancreatic cancer. Hepatogastroenterology. 2004;51:334-337.
29. Sears D, Erickson RA, Sayage-Rabie L, et al. TGF-beta and p53 staining in CT-guided and endoscopic ultrasound fine-needle aspirates of pancreatic adenocarcinoma. Dig Dis Sci. 2004;49:828-832.
30. Ni XG, Bai XF, Mao YL, et al. The clinical value of serum CEA, CA 19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. EJSO. 2005;31:164-169.
31. Pinto MM, Emanuel JR, Chaturvedi V, Costa J. Ki-ras mutations and the carcinoembryonic antigen level in fine needle aspirates of the pancreas. Acta Cytologica. 1997;41:427-434.
32. Ringel J, Lohr M. The MUC gene family: their role in diagnosis and early detection of pancreatic cancer. Mol Cancer. 2003;7:2-9.
33. Koopmann J, Fedarko NS, Jain A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2004;13:487-491.
34. Ortiz-Gonzalez J, Alvarez-Aguila NP, Medina-Castro JM. Adjusted carbohydrate antigen 19-9. Correlation with histological grade in pancreatic adenocarcinoma. Anticancer Res. 2005;25:3625-3627.
35. Cavelier G, Amzel LM. Mechanism of NAD(P)H:quinone reductase: Ab Initio studies of reduced flavin. Proteins. 2001;43:420-432.
36. Ross D, Kepa JK, Winski S, et al. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphism. Chem Biol Interact. 2000;129:77-97.
37. Ross D, Siegel D, Beall H, et al. DT-diaphorase in activation and detoxification of quinones. Cancer Metastasis Rev. 1993;12:83-101.
38. Riley RJ, Workman P. DT-diaphorase and cancer chemotherapy. Biochem Pharmacol. 1992;43:1657-1669.
39. Beyer RE, Segura-Aguilar J, Di Bernardo S, et al. The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. Proc Natl Acad Sci USA. 1996;93:2528-2532.
40. Siegel D, Bolton EM, Burr JA, et al. The reduction of α-tocopherolquinone by human NAD(P)H:quinone oxidoreductase: the role of a-toco pherolquinone as a cellular antioxidant. Mol Pharmacol. 1997;52:300-305.
41. Siegel D, Gustafson DL, Dehn DL, et al. NAD(P)H:quinone oxidoreductase 1 (NQO1): role as a superoxide scavenger. Mol Pharmacol. 2004;65:1-10.
42. Kinnula VL, Crapo JD. Superoxide dismutases in malignant cells and human tumors. Free Radic Biol Med. 2004;36:718-744.
43. Cullen JJ, Hinkhouse MM, Grady M, et al. Dicumarol inhibition of NAD(P)H:quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism. Cancer Res. 2003;63:5513-5520.
44. Aleksunes LM, Goedken M, Manautou JE. Up-regulation of NAD(P)H:quinone oxidoreductase 1 during human liver injury. World J Gastroenterol. 2006;12:1937-1940.
45. Belinsky M, Jaiswal AK. NAD(P)H:quinone oxidoreductase (DT-diaphorase) expression in normal and tumor tissue. Cancer Metastasis Rev. 1993;12:103-117.
46. Yantiss RK, Woda BA, Fanger GR, et al. KOC (K homology domain containing protein overexpressed in cancer) A novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol. 2005;29:188-195.
47. Suzuoki M, Miyamoto M, Kato K, et al. Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer. 2002;87:1140-1144.
48. Bai X-F, Ni X-G, Zhao P, et al. Overexpression of annexin 1 in pancreatic cancer and its clinical significance. World J Gastroenterol. 2004;10:1466-1470.
49. Traver RD, Siegel D, Beall HD, et al. Characterization of a polymorphism in NAD(P)H:quinone oxidoreductase (DT-diaphorase). Br J Cancer. 1997;75:69-75.
50. Siegel D, Anwar A, Winski SL, et al. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol Pharm. 2001;59:263-268.